4481

524348

AARTIDRUGS

img img img img
No Data Available

AARTI DRUGS LTD. Share Price Update

As of the latest trading session, AARTI DRUGS LTD. is trading at ₹382, down by ₹-0.89 or -0.23% from its previous close. The stock has moved between ₹378.00 and ₹382.00 today. Over the past year, the stock has delivered a return of -18.34%. In the last month, it has returned -3.27%.

AARTI DRUGS LTD. performance

Today’s low Today’s high
₹ 378.00 ₹ 382.00
₹ 382.90
52 week low 52 week high
₹ 318.95 ₹ 564.05
₹ 382.90
Open Price ₹ 379.50
Prev. Close ₹ 382.90
Volume (Shares) 78856.00
Total traded value ₹ 301.93
Upper Circuit ₹ 459.45
Lower Circuit ₹ 306.35
info

Investment Returns

Over 1 Month -3.27% Over 3 Months 7.16% Over 6 Months -8.06% Over 1 Year -18.34%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

AARTI DRUGS LTD. fundamentals


  • Market cap (Cr) 3,494.70
  • P/E Ratio (TTM) 20.63
  • Beta 0.95
  • Book Value / share 153.91
  • Return on equity 12.97%
  • EPS (TTM) 18.54
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 44.96
info icon alternate text
  • Market cap (Cr) 3,491.50
  • P/E Ratio (TTM) 20.63
  • Beta 0.92
  • Book Value / share 153.91
  • Return on equity 12.97%
  • EPS (TTM) 18.54
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 44.96
info icon alternate text

AARTI DRUGS LTD. Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 631.68
Operating Expense 573.94
Net Profit 44.96
Net Profit Margin (%) 7.11
Earnings Per Share (EPS) 4.93
EBITDA 80.11
Effective Tax Rate (%) 23.23
Particulars DEC 2025 (Values in Cr)
Revenue 528.80
Operating Expense 508.31
Net Profit 33.84
Net Profit Margin (%) 6.39
Earnings Per Share (EPS) 3.71
EBITDA 43.53
Effective Tax Rate (%) -55.87
Particulars SEP 2025 (Values in Cr)
Revenue 578.95
Operating Expense 523.31
Net Profit 41.78
Net Profit Margin (%) 7.21
Earnings Per Share (EPS) 4.58
EBITDA 75.34
Effective Tax Rate (%) 25.09
Particulars JUN 2025 (Values in Cr)
Revenue 520.96
Operating Expense 476.09
Net Profit 48.64
Net Profit Margin (%) 9.33
Earnings Per Share (EPS) 5.33
EBITDA 64.34
Effective Tax Rate (%) -7.49
Particulars MAR 2025 (Values in Cr)
Revenue 622.96
Operating Expense 554.00
Net Profit 61.48
Net Profit Margin (%) 9.86
Earnings Per Share (EPS) 6.74
EBITDA 90.36
Effective Tax Rate (%) 13.00
Particulars MAR 2026 (Values in Cr)
Revenue 2260.39
Operating Expense 2081.67
Net Profit 169.22
Net Profit Margin (%) 7.48
Earnings Per Share (EPS) 18.54
EBITDA 263.33
Effective Tax Rate (%) 6.66
Particulars MAR 2025 (Values in Cr)
Revenue 2173.65
Operating Expense 1988.47
Net Profit 157.31
Net Profit Margin (%) 7.23
Earnings Per Share (EPS) 17.18
EBITDA 276.22
Effective Tax Rate (%) 20.85
Particulars MAR 2024 (Values in Cr)
Revenue 2266.91
Operating Expense 2078.60
Net Profit 141.88
Net Profit Margin (%) 6.25
Earnings Per Share (EPS) 15.35
EBITDA 270.31
Effective Tax Rate (%) 26.28
Particulars MAR 2023 (Values in Cr)
Revenue 2497.97
Operating Expense 2295.39
Net Profit 152.81
Net Profit Margin (%) 6.11
Earnings Per Share (EPS) 16.50
EBITDA 284.63
Effective Tax Rate (%) 25.38
Particulars MAR 2022 (Values in Cr)
Revenue 2251.17
Operating Expense 2000.44
Net Profit 195.00
Net Profit Margin (%) 8.66
Earnings Per Share (EPS) 21.04
EBITDA 322.95
Effective Tax Rate (%) 23.67
Particulars MAR 2025 (Values in Cr)
Book Value / Share 149.99
ROE % 12.68
ROCE % 13.07
Total Debt to Total Equity 0.44
EBITDA Margin 12.84
Particulars MAR 2024 (Values in Cr)
Book Value / Share 139.40
ROE % 13.87
ROCE % 14.97
Total Debt to Total Equity 0.47
EBITDA Margin 12.85
Particulars MAR 2023 (Values in Cr)
Book Value / Share 128.77
ROE % 14.93
ROCE % 15.36
Total Debt to Total Equity 0.52
EBITDA Margin 11.47
Particulars MAR 2022 (Values in Cr)
Book Value / Share 111.92
ROE % 21.03
ROCE % 20.33
Total Debt to Total Equity 0.46
EBITDA Margin 13.82
Particulars MAR 2021 (Values in Cr)
Book Value / Share 98.01
ROE % 35.81
ROCE % 33.38
Total Debt to Total Equity 0.47
EBITDA Margin 20.66
Particulars MAR 2025 (Values in Cr)
Book Value / Share 137.10
ROE % 12.97
ROCE % 13.49
Total Debt to Total Equity 0.41
EBITDA Margin 12.82
Particulars MAR 2024 (Values in Cr)
Book Value / Share 127.83
ROE % 12.39
ROCE % 13.65
Total Debt to Total Equity 0.44
EBITDA Margin 12.06
Particulars MAR 2023 (Values in Cr)
Book Value / Share 120.34
ROE % 14.65
ROCE % 15.24
Total Debt to Total Equity 0.51
EBITDA Margin 11.54
Particulars MAR 2022 (Values in Cr)
Book Value / Share 104.99
ROE % 21.29
ROCE % 20.38
Total Debt to Total Equity 0.47
EBITDA Margin 14.48
Particulars MAR 2021 (Values in Cr)
Book Value / Share 92.23
ROE % 34.79
ROCE % 32.19
Total Debt to Total Equity 0.48
EBITDA Margin 21.46
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 7.56
Total Assets 2574.67
Total Liabilities 2574.67
Total Equity 1369.34
Share Outstanding 9
Price to Book Ratio 2.48
Return on Assets (%) 6.53
Return on Capital (%) 8.49
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 9.43
Total Assets 2432.35
Total Liabilities 2432.35
Total Equity 1281.95
Share Outstanding 9
Price to Book Ratio 3.39
Return on Assets (%) 7.04
Return on Capital (%) 9.29
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 8.95
Total Assets 2421.39
Total Liabilities 2421.39
Total Equity 1192.66
Share Outstanding 9
Price to Book Ratio 2.81
Return on Assets (%) 6.86
Return on Capital (%) 9.24
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 22.33
Total Assets 2207.95
Total Liabilities 2207.95
Total Equity 1036.30
Share Outstanding 9
Price to Book Ratio 4.09
Return on Assets (%) 9.28
Return on Capital (%) 13.02
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 9.77
Total Assets 1766.01
Total Liabilities 1766.01
Total Equity 913.40
Share Outstanding 9
Price to Book Ratio 7.53
Return on Assets (%) 15.87
Return on Capital (%) 22.29
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 4.57
Total Assets 2272.79
Total Liabilities 2272.79
Total Equity 1251.35
Share Outstanding 9
Price to Book Ratio 2.48
Return on Assets (%) 6.92
Return on Capital (%) 8.91
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 3.82
Total Assets 2171.61
Total Liabilities 2171.61
Total Equity 1175.20
Share Outstanding 9
Price to Book Ratio 3.39
Return on Assets (%) 6.53
Return on Capital (%) 8.61
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 2.67
Total Assets 2195.49
Total Liabilities 2195.49
Total Equity 1114.30
Share Outstanding 9
Price to Book Ratio 2.81
Return on Assets (%) 6.96
Return on Capital (%) 9.28
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.20
Total Assets 2034.52
Total Liabilities 2034.52
Total Equity 972.17
Share Outstanding 9
Price to Book Ratio 4.09
Return on Assets (%) 9.58
Return on Capital (%) 13.11
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 3.80
Total Assets 1637.00
Total Liabilities 1637.00
Total Equity 859.61
Share Outstanding 9
Price to Book Ratio 7.53
Return on Assets (%) 15.74
Return on Capital (%) 21.68
Particulars MAR 2025 (Values in Cr)
Net Income 211.77
Cash from Operations 299.70
Cash from Investing -164.63
Cash from Financing -82.11
Net change in Cash -2.16
Free Cash Flow 476.86
Particulars MAR 2024 (Values in Cr)
Net Income 235.52
Cash from Operations 421.32
Cash from Investing -223.65
Cash from Financing -136.03
Net change in Cash -0.76
Free Cash Flow 647.65
Particulars MAR 2023 (Values in Cr)
Net Income 224.18
Cash from Operations 192.99
Cash from Investing -163.97
Cash from Financing 16.54
Net change in Cash -14.10
Free Cash Flow 357.81
Particulars MAR 2022 (Values in Cr)
Net Income 269.95
Cash from Operations 153.79
Cash from Investing -149.63
Cash from Financing 92.02
Net change in Cash 12.79
Free Cash Flow 305.76
Particulars MAR 2021 (Values in Cr)
Net Income 369.01
Cash from Operations 251.62
Cash from Investing -71.77
Cash from Financing -81.12
Net change in Cash 2.04
Free Cash Flow 339.85
Particulars MAR 2025 (Values in Cr)
Net Income 198.75
Cash from Operations 272.02
Cash from Investing -134.91
Cash from Financing -84.59
Net change in Cash 0.56
Free Cash Flow 409.31
Particulars MAR 2024 (Values in Cr)
Net Income 192.48
Cash from Operations 388.33
Cash from Investing -187.09
Cash from Financing -148.80
Net change in Cash 1.20
Free Cash Flow 577.65
Particulars MAR 2023 (Values in Cr)
Net Income 204.81
Cash from Operations 216.52
Cash from Investing -131.13
Cash from Financing -30.53
Net change in Cash 0.02
Free Cash Flow 347.21
Particulars MAR 2022 (Values in Cr)
Net Income 255.49
Cash from Operations 119.98
Cash from Investing -125.35
Cash from Financing 84.11
Net change in Cash -1.35
Free Cash Flow 246.85
Particulars MAR 2021 (Values in Cr)
Net Income 337.71
Cash from Operations 241.95
Cash from Investing -69.03
Cash from Financing -85.27
Net change in Cash -0.13
Free Cash Flow 322.72
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 35.29 14.58 1.70 270.44 23.12 38.50
BLISS GVS PHARMA LTD. 402.00 32.52 3.56 4252.72 118.35 437.40
CIPLA LTD. 1390.85 27.54 3.26 112352.94 1165.55 1672.20
FERMENTA BIOTECH LIMITED 300.35 13.25 2.17 883.96 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 35.29 24.68 4.54 270.44 23.12 38.50
AMRUTANJAN HEALTH CARE LTD. 558.20 25.02 4.35 1613.79 490.00 789.95
ASTRAZENECA PHARMA INDIA LTD. 8724.25 113.94 24.98 21810.63 7630.00 10653.05
BLISS GVS PHARMA LTD. 402.00 43.23 3.68 4252.72 118.35 437.40

AARTI DRUGS LTD. shareholding pattern

Holding
33.17%
55.02%
1.57%
10.21%
2.47%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

AARTI DRUGS LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
382.90 0.65 redarrow
red-green-graph indicator
8 Bearish
8 Bullish
  • 5 Days 385.20
  • 26 Days 379.10
  • 10 Days 384.20
  • 50 Days 375.00
  • 12 Days 383.60
  • 100 Days 381.50
  • 20 Days 381.00
  • 200 Days 403.40
383.88 PIVOT
First Support 374.02 First Resistance 390.27 Second Support 367.63 Second Resistance 400.13 Third Support 357.77 Third Resistance 406.52
RSI 52.76 ADX 18.42 MACD 4.49 Williams % R -47.55 Commodity Channel Index (CCI) 6.80
Date 2026-06-01 Week 79779.00 Same Day 37227.00 Month 84033.00
1 Year 0.96 3 Year 0.76
Over 1 Month
-3.27% down
Over 1 Year
-18.34% down
Over 3 Months
7.16% down
Over 3 Years
-5.56% down
Over 6 Months
-8.06% down
Over 5 Years
-12.26% down

AARTI DRUGS LTD. Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
09 Feb 2026 2.0 Interim 09 Feb 2026 Equity shares
04 Feb 2025 1.0 Interim 04 Feb 2025 Equity shares
06 Feb 2024 1.0 Interim 06 Feb 2024 Equity shares
08 Feb 2023 1.0 Interim 08 Feb 2023 Equity shares
09 Feb 2022 1.0 Interim 10 Feb 2022 Equity shares
03 Nov 2020 2.5 Interim 04 Nov 2020 Equity shares
17 Feb 2020 2.0 Interim 18 Feb 2020 Equity shares
26 Jul 2019 1.0 Final 30 Jul 2019 Equity shares
01 Aug 2018 1.0 Final 03 Aug 2018 Equity shares
09 Aug 2017 1.0 Final 11 Aug 2017 Equity shares
22 Mar 2016 3.0 Interim 3 24 Mar 2016 Equity shares
12 Feb 2016 1.5 Interim 2 15 Feb 2016 Equity shares
10 Nov 2015 2.25 Interim 14 Nov 2015 Equity shares
05 Aug 2015 3.0 Final 07 Aug 2015 Equity shares
04 Feb 2015 5.0 Interim 2 05 Feb 2015 Equity shares
19 Nov 2014 5.0 Interim 1 20 Nov 2014 Equity shares
02 Jul 2014 5.5 Final 04 Jul 2014 Equity shares
05 Feb 2014 4.5 Interim 2 06 Feb 2014 Equity shares
19 Nov 2013 3.0 Interim 14 Nov 2013 Equity shares
24 Jul 2013 4.0 Final 26 Jul 2013 Equity shares
11 Feb 2013 3.0 Interim 2 12 Feb 2013 Equity shares
05 Nov 2012 3.0 Interim 06 Nov 2012 Equity shares
17 Aug 2012 3.0 Final 22 Aug 2012 Equity shares
06 Feb 2012 2.0 Interim 07 Feb 2012 Equity shares
14 Jul 2011 2.5 Final 16 Jul 2011 Equity shares
07 Feb 2011 2.5 Interim 08 Feb 2011 Equity shares
18 Aug 2010 5.0 Final 21 Aug 2010 Equity shares
23 Jul 2009 3.0 Final 25 Jul 2009 Equity shares
13 Aug 2008 1.8 Final 16 Aug 2008 Equity shares
20 Mar 2007 1.2 Final 21 Mar 2007 Equity shares
27 Jul 2005 0.0 Final 29 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
01 Oct 2020 30 Sep 2020 3:1
25 Mar 2015 24 Mar 2015 1:1
11 Jun 1996 13 May 1996 1:2
Dividend date Dividend amount Dividend type Record date Instrument type
09 Feb 2026 2.0 Interim 09 Feb 2026 Equity shares
04 Feb 2025 1.0 Interim 04 Feb 2025 Equity shares
06 Feb 2024 1.0 Interim 06 Feb 2024 Equity shares
08 Feb 2023 1.0 Interim 08 Feb 2023 Equity shares
09 Feb 2022 1.0 Interim 10 Feb 2022 Equity shares
03 Nov 2020 2.5 Interim 04 Nov 2020 Equity shares
17 Feb 2020 2.0 Interim 18 Feb 2020 Equity shares
26 Jul 2019 1.0 Final 30 Jul 2019 Equity shares
01 Aug 2018 1.0 Final 03 Aug 2018 Equity shares
09 Aug 2017 1.0 Final 11 Aug 2017 Equity shares
22 Mar 2016 3.0 Interim 3 24 Mar 2016 Equity shares
12 Feb 2016 1.5 Interim 2 15 Feb 2016 Equity shares
10 Nov 2015 2.25 Interim 14 Nov 2015 Equity shares
05 Aug 2015 3.0 Final 07 Aug 2015 Equity shares
04 Feb 2015 5.0 Interim 2 05 Feb 2015 Equity shares
19 Nov 2014 5.0 Interim 1 20 Nov 2014 Equity shares
02 Jul 2014 5.5 Final 04 Jul 2014 Equity shares
05 Feb 2014 4.5 Interim 2 06 Feb 2014 Equity shares
19 Nov 2013 3.0 Interim 14 Nov 2013 Equity shares
24 Jul 2013 4.0 Final 26 Jul 2013 Equity shares
11 Feb 2013 3.0 Interim 2 12 Feb 2013 Equity shares
05 Nov 2012 3.0 Interim 06 Nov 2012 Equity shares
17 Aug 2012 3.0 Final 22 Aug 2012 Equity shares
06 Feb 2012 2.0 Interim 07 Feb 2012 Equity shares
14 Jul 2011 2.5 Final 16 Jul 2011 Equity shares
07 Feb 2011 2.5 Interim 08 Feb 2011 Equity shares
18 Aug 2010 5.0 Final 21 Aug 2010 Equity shares
23 Jul 2009 3.0 Final 25 Jul 2009 Equity shares
13 Aug 2008 1.8 Final 16 Aug 2008 Equity shares
20 Mar 2007 1.2 Final 21 Mar 2007 Equity shares
27 Jul 2005 0.0 Final 29 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
01 Oct 2020 30 Sep 2020 3:1
25 Mar 2015 24 Mar 2015 1:1
11 Jun 1996 13 May 1996 1:2

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Aarti Drugs Ltd?

Answer Field

Aarti Drugs Ltd share price is for NSE ₹ 382.00 & for BSE ₹ 380.45 as on Jun 02 2026 09:26 AM.

What is the Market Cap of Aarti Drugs Ltd Share?

Answer Field

The market cap of Aarti Drugs Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jun 02 2026 09:26 AM.

What is the 52 Week High and Low of Aarti Drugs Ltd?

Answer Field

The 52 Week High and Low of Aarti Drugs Ltd for NSE is ₹ 564.05 and ₹ 318.95 and for BSE is ₹ 574.95 and ₹ 318.60.

What is 1 year return for Aarti Drugs Ltd?

Answer Field

The 1 year returns on the stock has been -18.34%.

What is the P/E Ratio of Aarti Drugs Ltd Share?

Answer Field

As on Jun 02 2026 09:26 AM the price-to-earnings (PE) ratio for Aarti Drugs Ltd share is 20.63.

What is the PB ratio of Aarti Drugs Ltd Share?

Answer Field

As on Jun 02 2026 09:26 AM, the price-to-book (PB) ratio for Aarti Drugs Ltd share is 153.91.

How to Buy Aarti Drugs Ltd Share?

Answer Field

You can trade in Aarti Drugs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Aarti Drugs Ltd Share on Bajaj Broking App?

Answer Field

To buy Aarti Drugs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Aarti Drugs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|